Clinical Research Directory
Browse clinical research sites, groups, and studies.
Mavacamten in Adult Patients With Obstructive Hypertrophic Cardiomyopathy
Sponsor: Chinese Academy of Medical Sciences, Fuwai Hospital
Summary
This retrospective cohort study aims to evaluate the clinical efficacy and safety of mavacamten in adult patients with obstructive hypertrophic cardiomyopathy (oHCM). A total of 222 patients were included and categorized based on treatments received in routine clinical practice into a mavacamten group and a standard therapy group. The primary outcome is the change in resting left ventricular outflow tract (LVOT) gradient at Week 30. Secondary outcomes include changes in Valsalva LVOT gradient, New York Heart Association (NYHA) functional class, cardiac biomarkers, and echocardiographic parameters. Safety outcomes include adverse events and left ventricular systolic dysfunction. This study provides real-world evidence on the effectiveness and safety of mavacamten in Chinese patients with oHCM.
Official title: Mavacamten for Improving Cardiac Function and Clinical Outcomes in Adult Patients With Obstructive Hypertrophic Cardiomyopathy: A Retrospective Cohort Study
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
222
Start Date
2024-01-01
Completion Date
2025-06-30
Last Updated
2026-04-17
Healthy Volunteers
No
Interventions
mavacamten
Mavacamten was administered as part of routine clinical care for patients with obstructive hypertrophic cardiomyopathy. This observational study did not assign interventions; instead, patients were categorized based on treatments received in real-world clinical practice. The initial dose was 2.5 mg once daily, with dose adjustments based on left ventricular ejection fraction and LVOT gradient as clinically indicated.
Locations (1)
Fuwai Central China Cardiovascular Hospital
Zhengzhou, Henan, China